Concepedia

LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study

Julien Mazières, T.M. Kim, Boon Khaw Lim, Marie Wislez, Christophe Dooms, Giovanna Finocchiaro, H. Hayashi, Chong Kin Liam, Jo Raskin, L.M. Tho,

Annals of Oncology · 2022 · 40 citations · 0 references

DOI

Concepts